FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3109385812> ?p ?o ?g. }

• W3109385812 endingPage "100685" @default.
• W3109385812 startingPage "100685" @default.
• W3109385812 abstract "For locally advanced esophageal cancer, concurrent chemoradiotherapy (CRT) followed by surgery has been a standard treatment, while clinical studies showed comparable survival outcomes between definitive CRT and neoadjuvant CRT followed by surgery in patients responding to CRT. Thus, biomarkers are required to predict treatment outcomes and benefit of adding surgery after CRT. This prospective biomarker study examined the role of cell-free DNA (cfDNA) fragmentation profiles and genomic copy number variations (CNVs) in predicting treatment outcomes in esophageal squamous cell carcinoma patients treated with neoadjuvant or definitive CRT. The clinical response was evaluated after induction chemotherapy and after CRT. Fragment Ratio (FR)-score and I-score were calculated from plasma cfDNA reflecting fragment lengths and CNV of cfDNA, respectively. The association between indices of cfDNA (cfDNA concentration, FR-score, and I-score) and treatment outcomes (clinical response, time to progression [TTP], and overall survival [OS]) were evaluated. Sixty-one patients were included. Thirty patients received neoadjuvant CRT followed by surgery, whereas 31 received definitive CRT. Low baseline, post-induction chemotherapy, and post-CRT FR-scores and low post-induction I-score were significantly associated with improved treatment response (P < 0.05). Additionally, patients with surgery after CRT showed significantly longer survival than patients without surgery in the FR-score-high group (median TTP, 12.7 vs 3.4 months; P = 0.011; OS, not reached vs 12.9 months; P = 0.02), while there was no survival benefit with surgery in the FR-score-low group. FR-score may be a new biomarker to predict treatment response, residual tumor burden after CRT, and consequently, survival benefit of adding morbid surgery after CRT. FR-score has strength in a relatively simple and inexpensive methodology compared to deep sequencing, resulting in high availability and accessibility, despite limited sensitivity." @default.
• W3109385812 created "2020-12-07" @default.
• W3109385812 creator A5020681771 @default.
• W3109385812 creator A5027135040 @default.
• W3109385812 creator A5034805413 @default.
• W3109385812 creator A5035182573 @default.
• W3109385812 creator A5039472076 @default.
• W3109385812 creator A5048166383 @default.
• W3109385812 creator A5055461839 @default.
• W3109385812 creator A5089383440 @default.
• W3109385812 date "2021-06-01" @default.
• W3109385812 modified "2023-10-06" @default.
• W3109385812 title "Genome-wide and size-based cell-free DNA indices as predictive biomarkers for locally advanced esophageal squamous cell carcinoma treated with preoperative or definitive chemoradiotherapy" @default.
• W3109385812 cites W2011964243 @default.
• W3109385812 cites W2019607817 @default.
• W3109385812 cites W2020896272 @default.
• W3109385812 cites W2033756944 @default.
• W3109385812 cites W2066277837 @default.
• W3109385812 cites W2108234281 @default.
• W3109385812 cites W2108549165 @default.
• W3109385812 cites W2122166737 @default.
• W3109385812 cites W2122769974 @default.
• W3109385812 cites W2140575188 @default.
• W3109385812 cites W2140625837 @default.
• W3109385812 cites W2154444715 @default.
• W3109385812 cites W2464284977 @default.
• W3109385812 cites W2479773785 @default.
• W3109385812 cites W2530313893 @default.
• W3109385812 cites W2570401594 @default.
• W3109385812 cites W2883297454 @default.
• W3109385812 cites W2885107163 @default.
• W3109385812 cites W2889646458 @default.
• W3109385812 cites W2900295924 @default.
• W3109385812 cites W2922148642 @default.
• W3109385812 cites W2944104549 @default.
• W3109385812 cites W2947989913 @default.
• W3109385812 cites W2956617819 @default.
• W3109385812 cites W2957286572 @default.
• W3109385812 cites W2966632204 @default.
• W3109385812 cites W2973124515 @default.
• W3109385812 cites W2985165646 @default.
• W3109385812 cites W3003142943 @default.
• W3109385812 cites W3026958615 @default.
• W3109385812 cites W3027714810 @default.
• W3109385812 cites W4234746319 @default.
• W3109385812 cites W4235642752 @default.
• W3109385812 doi "https://doi.org/10.1016/j.currproblcancer.2020.100685" @default.
• W3109385812 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33342577" @default.
• W3109385812 hasPublicationYear "2021" @default.
• W3109385812 type Work @default.
• W3109385812 sameAs 3109385812 @default.
• W3109385812 citedByCount "5" @default.
• W3109385812 countsByYear W31093858122021 @default.
• W3109385812 countsByYear W31093858122022 @default.
• W3109385812 countsByYear W31093858122023 @default.
• W3109385812 crossrefType "journal-article" @default.
• W3109385812 hasAuthorship W3109385812A5020681771 @default.
• W3109385812 hasAuthorship W3109385812A5027135040 @default.
• W3109385812 hasAuthorship W3109385812A5034805413 @default.
• W3109385812 hasAuthorship W3109385812A5035182573 @default.
• W3109385812 hasAuthorship W3109385812A5039472076 @default.
• W3109385812 hasAuthorship W3109385812A5048166383 @default.
• W3109385812 hasAuthorship W3109385812A5055461839 @default.
• W3109385812 hasAuthorship W3109385812A5089383440 @default.
• W3109385812 hasConcept C121608353 @default.
• W3109385812 hasConcept C126322002 @default.
• W3109385812 hasConcept C141071460 @default.
• W3109385812 hasConcept C143998085 @default.
• W3109385812 hasConcept C185592680 @default.
• W3109385812 hasConcept C188816634 @default.
• W3109385812 hasConcept C2776611710 @default.
• W3109385812 hasConcept C2776694085 @default.
• W3109385812 hasConcept C2777546739 @default.
• W3109385812 hasConcept C2778292576 @default.
• W3109385812 hasConcept C2778424827 @default.
• W3109385812 hasConcept C2779742542 @default.
• W3109385812 hasConcept C2781197716 @default.
• W3109385812 hasConcept C2994415158 @default.
• W3109385812 hasConcept C530470458 @default.
• W3109385812 hasConcept C55493867 @default.
• W3109385812 hasConcept C71924100 @default.
• W3109385812 hasConceptScore W3109385812C121608353 @default.
• W3109385812 hasConceptScore W3109385812C126322002 @default.
• W3109385812 hasConceptScore W3109385812C141071460 @default.
• W3109385812 hasConceptScore W3109385812C143998085 @default.
• W3109385812 hasConceptScore W3109385812C185592680 @default.
• W3109385812 hasConceptScore W3109385812C188816634 @default.
• W3109385812 hasConceptScore W3109385812C2776611710 @default.
• W3109385812 hasConceptScore W3109385812C2776694085 @default.
• W3109385812 hasConceptScore W3109385812C2777546739 @default.
• W3109385812 hasConceptScore W3109385812C2778292576 @default.
• W3109385812 hasConceptScore W3109385812C2778424827 @default.
• W3109385812 hasConceptScore W3109385812C2779742542 @default.
• W3109385812 hasConceptScore W3109385812C2781197716 @default.
• W3109385812 hasConceptScore W3109385812C2994415158 @default.
• W3109385812 hasConceptScore W3109385812C530470458 @default.
• W3109385812 hasConceptScore W3109385812C55493867 @default.
• W3109385812 hasConceptScore W3109385812C71924100 @default.

• next